SGEN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 Dec 2023 @ 16:00):

Stats
Today's Volume	19.39M
Average Volume	1.63M
Market Cap	43.15B
EPS	$0 ( 2024-02-21 )
Next earnings date	( $0 ) 2024-04-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.19
ATR14	$1.424 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Baker Bros. Advisors Lp	Sell	42 977 301	Common Stock
2023-12-14	Baker Bros. Advisors Lp	Sell	8 750	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 44 783 214

Volume Correlation

Long: 0.24 (neutral)

Short: 0.00 (neutral)

Signal:(82.918) Neutral

Seattle Genetics Inc Correlation

10 Most Positive Correlations
MLTX	0.927
BLPH	0.927
LGST	0.924
INTA	0.918
SJ	0.917
MOTNU	0.911
MORF	0.907
SVFC	0.907
PESI	0.903
DSEY	0.903

10 Most Negative Correlations
ESSA	-0.937
BSRR	-0.937
FNCB	-0.936
SIRI	-0.934
APEI	-0.921
BRKL	-0.92
BLFY	-0.919
ONEM	-0.916
FLIC	-0.913
BCOW	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Seattle Genetics Inc Correlation - Currency/Commodity

0.88
( strong )

0.82
( strong )

0.79
( moderate )

-0.43
( neutral )

0.63
( weak )

-0.52
( weak negative )

Seattle Genetics Inc Financials

Annual	2022
Revenue:	$1.96B
Gross Profit:	$1.55B (79.10 %)
EPS:	$-3.30

Q3	2023
Revenue:	$648.65M
Gross Profit:	$483.40M (74.52 %)
EPS:	$-1.150

Q2	2023
Revenue:	$603.83M
Gross Profit:	$423.08M (70.07 %)
EPS:	$-1.130

Q1	2023
Revenue:	$519.72M
Gross Profit:	$407.94M (78.49 %)
EPS:	$-0.930

Financial Reports:

No articles found.

Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Realtime updates for Seattle Genetics Inc [SGEN]

Upcoming Earnings Alert